Navitoclax
- Generic Name
- Navitoclax
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C47H55ClF3N5O6S3
- CAS Number
- 923564-51-6
- Unique Ingredient Identifier
- XKJ5VVK2WD
- Background
Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others.
Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying.
- Associated Conditions
- -
- Associated Therapies
- -
No trials found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath